糖果派对

In particular, his insight into project collaboration across industry and hospital will come into play in the professorship – an area that will be prioritised in the coming period by the Faculty of Health and Medical Sciences at 糖果派对 and Odense University Hospital (OUH).

Thomas Emil Andersen has a background as a molecular biologist from the University of Southern Denmark (糖果派对). After graduating in 2005, he was employed as a researcher at NKT Research until 2009. During his employment, he completed an Industrial PhD programme as one of the first under this scheme.

Thomas Emil Andersen then chose to pursue an academic career and after a postdoc course at the Department of Clinical Microbiology at OUH/糖果派对, he was employed in a combination position as a senior researcher and associate professor at the Department of Clinical Microbiology.

The connection to industry has been a common thread in Thomas Emil Andersen's research. He has participated in a large number of innovation projects in collaboration with pharma and medical device companies. Today, he has built up a research group that actively contributes to the development of health technology, pharmaceuticals and vaccines, as well as new techniques for identification and analysis of bacteria.

In parallel with the innovation projects, Thomas Emil Andersen's group conducts research into various infectious diseases that are particularly relevant to hospital patients. A special focus here has been on urinary tract infections, which Thomas Emil Andersen has researched since the 00s. For this research, he has built up a comprehensive model platform with animal and cell culture models from scratch, which has contributed important advances in the field of research. The platform and the built-up know-how are currently used in the development of new drugs, vaccines and catheters in collaboration with other university groups, hospital units, and industry.

A number of foundation grants have supported Thomas Emil Andersen's work, where he and his partners have received more than DKK 140 million in project funding over the past 15 years. His research has been published in 70 original research articles, with first or senior authorship in 36. The work has been published in leading journals in several areas, including Cancer Cell, Kidney International, Clinical Microbiology and Infection, Biomaterials, Nature Communications and Nature Reviews Gastroenterology and Hepatology.

Early in the corona pandemic, Thomas Emil Andersen received funding from the Novo Nordisk Foundation to establish the Region of Southern Denmark's first virus culture laboratory in Winsløwparken, Odense. In collaboration with the Department of Infectious Diseases and other hospital departments at OUH, he coordinated several studies of, among other things, the effect of COVID-19 vaccines on new virus variants. This work contributed to creating an overview of the effect of the vaccines in vulnerable patient groups and the infectiousness of this virus. Currently, he is leading a study of infectiousness and the need for isolation in respiratory virus-infected patients, in a collaborative project between OUH and Lillebælt Hospital.

In his private life, Thomas Emil Andersen is an active exerciser and often spends his time on do-it-yourself projects in the house and garden. He often travels south to the Alps throughout the year, where he and his family practice skiing and mountain biking. Thomas Emil Andersen is 48 years old, married to nurse Pia Stillenmunkes and father to teenage boys Carl-Emil, Mikkel and Hugo, aged 15, 17 and 19.

POB: Nuuk, Greenland, 070476